JP2016515131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515131A5 JP2016515131A5 JP2016502329A JP2016502329A JP2016515131A5 JP 2016515131 A5 JP2016515131 A5 JP 2016515131A5 JP 2016502329 A JP2016502329 A JP 2016502329A JP 2016502329 A JP2016502329 A JP 2016502329A JP 2016515131 A5 JP2016515131 A5 JP 2016515131A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- pharmaceutically acceptable
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 46
- 239000000651 prodrug Substances 0.000 claims description 29
- 229940002612 prodrugs Drugs 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000011780 sodium chloride Substances 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 210000004027 cells Anatomy 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 230000012846 protein folding Effects 0.000 claims description 6
- 150000004820 halides Chemical class 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 102000011045 Chloride Channels Human genes 0.000 claims description 2
- 108010062745 Chloride Channels Proteins 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 230000035695 Efflux Effects 0.000 claims description 2
- 229940093912 Gynecological Sulfonamides Drugs 0.000 claims description 2
- 210000004072 Lung Anatomy 0.000 claims description 2
- 210000001552 airway epithelial cell Anatomy 0.000 claims description 2
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 201000003883 cystic fibrosis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002919 epithelial cells Anatomy 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 claims description 2
- 230000003834 intracellular Effects 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229940026752 topical Sulfonamides Drugs 0.000 claims description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 2
- 0 *c(c(*)c1*)c(*)c(*)c1NIC1=Cc(cccc2Cl)c2OC1=O Chemical compound *c(c(*)c1*)c(*)c(*)c1NIC1=Cc(cccc2Cl)c2OC1=O 0.000 description 6
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
Description
添付の特許請求の範囲の化合物及び方法は、本明細書に説明される特定の化合物及び方法による範囲に限定されるものではなく、特許請求の範囲のうちの少数の態様の例示として意図され、機能的に均等である任意の化合物及び方法は、本開示の範囲内である。本明細書に示されかつ説明されるものに加えて、化合物及び方法の種々の修正は、添付の特許請求の範囲内に属することを意図する。更には、特定の代表的な化合物、方法、及びこれらの化合物及び方法の態様のみが具体的に説明されるが、他の化合物及び方法が、添付の特許請求の範囲内に属することを意図する。したがって、ステップ、要素、成分、または構成物の組み合わせが、明示的に記述され得るが、ステップ、要素、成分、及び構成物の全ての他の組み合わせが、明示的に記されなくとも含まれる。
例えば、本発明は以下の項目を提供する。
(項目1)
以下の式の化合物、
またはその薬学的に許容される塩もしくはプロドラッグであって、式中、
R 1 が、水素、ハロゲン、ヒドロキシル、置換もしくは非置換のアルコキシル、置換もしくは非置換のアミノ、置換もしくは非置換のC 1−6 アルキル、または置換もしくは非置換のヘテロシクロアルキルであり、
R 2 が、水素、ハロゲン、ヒドロキシル、ニトロ、シアノ、アジド、チオシアネート、トリフルオロメチル、置換もしくは非置換のアルコキシル、置換もしくは非置換のアミノ、置換もしくは非置換のカルボニル、または置換もしくは非置換のC 1−6 アルキルであり、
R 3 が、水素または置換もしくは非置換のC 1−6 アルキルであり、
R 4 が、置換もしくは非置換のC 1−6 アルキル、置換もしくは非置換のアリール、または置換もしくは非置換のヘテロアリールであり、
Xが、SまたはOであり、
Yが、O、NH、またはNCH 3 である、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。
(項目2)
前記化合物が、
からなる群から選択され、式中、R 5 、R 6 、R 7 、R 8 、及びR 9 が、各々独立して、水素、ハロゲン、ヒドロキシル、置換もしくは非置換のアルコキシ、シアノ、ニトロ、トリフルオロメチル、置換もしくは非置換のカルボニル、置換もしくは非置換のアミノ、置換もしくは非置換のC 1−6 アルキル、置換もしくは非置換のC 2−6 アルケニル、置換もしくは非置換のアリール、置換もしくは非置換のスルホンアミド、置換もしくは非置換のスルホニル、または置換もしくは非置換のチオから選択され、
随意に、R 1 及びR 2 、R 5 及びR 6 、R 6 及びR 7 、R 7 及びR 8 、またはR 8 及びR 9 が、組み合わさって、置換もしくは非置換のアリール、置換もしくは非置換のシクロアルケニル、置換もしくは非置換のヘテロアリール、または置換もしくは非置換のヘテロシクロアルキルを形成する、項目1に記載の化合物。
(項目3)
以下の式の化合物、
またはその薬学的に許容される塩もしくはプロドラッグであって、式中、
Lが、ヘテロアリールであり、
R 5 、R 6 、R 7 、R 8 、及びR 9 が、各々独立して、水素及びメトキシから選択される、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。
(項目4)
以下の式の化合物、
またはその薬学的に許容される塩もしくはプロドラッグであって、式中、
X 1 、X 2 、X 3 、及びX 4 が、各々独立して、CH及びNから選択され、
Yが、OまたはNRであり、式中、Rが、水素またはメチルであり、
R 2 が、水素、C 1−6 アルキル、ハロゲン、またはトリフルオロアルキルであり、
R 5 、R 6 、R 7 、R 8 、及びR 9 が、各々独立して、水素及びメトキシから選択される、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。
(項目5)
以下の式の化合物、
またはその薬学的に許容される塩もしくはプロドラッグであって、式中、
X 1 が、OまたはNCH 3 であり、
X 2 が、CHまたはNであり、
Yが、O、NH、またはNCH 3 であり、
R 5 、R 6 、R 7 、R 8 、及びR 9 が、各々独立して、水素及びメトキシから選択される、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。
(項目6)
以下の式の化合物、
またはその薬学的に許容される塩もしくはプロドラッグであって、式中、
R 1 及びR 2 が、各々独立して、水素、置換もしくは非置換のアミノ、及び置換もしくは非置換のカルボニルから選択される、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。
(項目7)
以下の式の化合物、
またはその薬学的に許容される塩もしくはプロドラッグであって、式中、
Xが、CH 2 、NH、またはOである、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。
(項目8)
項目1〜7に記載の化合物のうちの1つ以上及び薬学的に許容される担体を含む、組成物。
(項目9)
項目1〜7のいずれかに記載の有効量の化合物を前記対象に投与することを含む、対象のタンパク質フォールディング障害の治療のための方法。
(項目10)
前記タンパク質フォールディング障害が、嚢胞性線維症である、項目9に記載の方法。
(項目11)
前記タンパク質フォールディング障害が、慢性閉塞性肺疾患である、項目9に記載の方法。
(項目12)
CFTR変異を内因的に発現する細胞を、項目1〜7のいずれかに記載の化合物と接触させることを含む、細胞内のハロゲン化物流出をレスキューする方法。
(項目13)
前記CFTR変異が、delF508−CFTRである、項目12に記載の方法。
(項目14)
前記ハロゲン化物流出が、塩化物流出である、項目12または13に記載の方法。
(項目15)
delF508−CFTR変異を発現する細胞を、項目1〜7のいずれかに記載の化合物と接触させることを含む、前細胞内のdelF508−CFTRタンパク質のプロセシング欠陥を修正する方法。
(項目16)
前記細胞が、CFヒト気道上皮細胞である、項目12〜15のいずれかに記載の方法。
(項目17)
前記細胞が、CFヒト肺である、項目12〜15のいずれかに記載の方法。
(項目18)
細胞内の機能的delF508−CFTR塩化物チャネルを修正する方法であって、
分極上皮細胞である細胞を、項目1〜7のいずれかに記載の化合物と接触させることを含む方法。
(項目19)
前記方法が、インビトロで実施される、項目12〜18のいずれかに記載の方法。
(項目20)
前記方法が、インビボで実施される、項目12〜18のいずれかに記載の方法。
The compounds and methods of the appended claims are not intended to be limited to the scope of the specific compounds and methods described herein, but are intended to be exemplary of a few aspects of the claims, Any compounds and methods that are functionally equivalent are within the scope of this disclosure. In addition to what is shown and described herein, various modifications of the compounds and methods are intended to fall within the scope of the appended claims. Moreover, while only specific representative compounds and methods and embodiments of these compounds and methods are specifically described, other compounds and methods are intended to fall within the scope of the appended claims. . Thus, a combination of steps, elements, components or components may be explicitly described, but all other combinations of steps, elements, components and components are included even if not explicitly stated.
For example, the present invention provides the following items.
(Item 1)
A compound of the formula
Or a pharmaceutically acceptable salt or prodrug thereof, wherein
R 1 is hydrogen, halogen, hydroxyl, substituted or unsubstituted alkoxyl, substituted or unsubstituted amino, substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted heterocycloalkyl,
R 2 is hydrogen, halogen, hydroxyl, nitro, cyano, azide, thiocyanate, trifluoromethyl, substituted or unsubstituted alkoxyl, substituted or unsubstituted amino, substituted or unsubstituted carbonyl, or substituted or unsubstituted C 1-6 alkyl,
R 3 is hydrogen or substituted or unsubstituted C 1-6 alkyl;
R 4 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl,
X is S or O;
The compound, or a pharmaceutically acceptable salt or prodrug thereof, wherein Y is O, NH, or NCH 3 .
(Item 2)
The compound is
Wherein R 5 , R 6 , R 7 , R 8 , and R 9 are each independently hydrogen, halogen, hydroxyl, substituted or unsubstituted alkoxy, cyano, nitro, tri Fluoromethyl, substituted or unsubstituted carbonyl, substituted or unsubstituted amino, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted Selected from sulfonamides, substituted or unsubstituted sulfonyls, or substituted or unsubstituted thios,
Optionally, R 1 and R 2 , R 5 and R 6 , R 6 and R 7 , R 7 and R 8 , or R 8 and R 9 are combined to form a substituted or unsubstituted aryl, substituted or unsubstituted 2. The compound of item 1, wherein said compound forms a cycloalkenyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
(Item 3)
A compound of the formula
Or a pharmaceutically acceptable salt or prodrug thereof, wherein
L is heteroaryl;
The compound, or pharmaceutically acceptable salt or prodrug thereof, wherein R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from hydrogen and methoxy.
(Item 4)
A compound of the formula
Or a pharmaceutically acceptable salt or prodrug thereof, wherein
X 1 , X 2 , X 3 , and X 4 are each independently selected from CH and N;
Y is O or NR, wherein R is hydrogen or methyl;
R 2 is hydrogen, C 1-6 alkyl, halogen, or trifluoroalkyl;
The compound, or pharmaceutically acceptable salt or prodrug thereof, wherein R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from hydrogen and methoxy.
(Item 5)
A compound of the formula
Or a pharmaceutically acceptable salt or prodrug thereof, wherein
X 1 is O or NCH 3 ;
X 2 is CH or N;
Y is O, NH, or NCH 3 ;
The compound, or pharmaceutically acceptable salt or prodrug thereof, wherein R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from hydrogen and methoxy.
(Item 6)
A compound of the formula
Or a pharmaceutically acceptable salt or prodrug thereof, wherein
The compound, or pharmaceutically acceptable salt or prodrug thereof, wherein R 1 and R 2 are each independently selected from hydrogen, substituted or unsubstituted amino, and substituted or unsubstituted carbonyl.
(Item 7)
A compound of the formula
Or a pharmaceutically acceptable salt or prodrug thereof, wherein
The compound, or a pharmaceutically acceptable salt or prodrug thereof, wherein X is CH 2 , NH, or O.
(Item 8)
8. A composition comprising one or more of the compounds of items 1-7 and a pharmaceutically acceptable carrier.
(Item 9)
8. A method for treating a protein folding disorder in a subject comprising administering to the subject an effective amount of a compound according to any of items 1-7.
(Item 10)
Item 10. The method according to Item 9, wherein the protein folding disorder is cystic fibrosis.
(Item 11)
Item 10. The method according to Item 9, wherein the protein folding disorder is chronic obstructive pulmonary disease.
(Item 12)
A method for rescue of intracellular halide efflux, comprising contacting a cell that endogenously expresses a CFTR mutation with a compound according to any of items 1 to 7.
(Item 13)
13. The method of item 12, wherein the CFTR mutation is delF508-CFTR.
(Item 14)
14. A method according to item 12 or 13, wherein the halide effluent is a chloride effluent.
(Item 15)
A method for correcting a processing defect of a delF508-CFTR protein in a precell, comprising contacting a cell expressing a delF508-CFTR mutation with a compound according to any of items 1-7.
(Item 16)
Item 16. The method according to any one of Items 12 to 15, wherein the cell is a CF human airway epithelial cell.
(Item 17)
Item 16. The method according to any one of Items 12 to 15, wherein the cell is CF human lung.
(Item 18)
A method of modifying a functional delF508-CFTR chloride channel in a cell comprising:
A method comprising contacting a cell that is a polarized epithelial cell with a compound according to any one of items 1 to 7.
(Item 19)
19. A method according to any of items 12-18, wherein the method is performed in vitro.
(Item 20)
19. A method according to any of items 12-18, wherein the method is performed in vivo.
Claims (20)
R1が、水素、ハロゲン、ヒドロキシル、置換もしくは非置換のアルコキシル、置換もしくは非置換のアミノ、置換もしくは非置換のC1−6アルキル、または置換もしくは非置換のヘテロシクロアルキルであり、
R2が、水素、ハロゲン、ヒドロキシル、ニトロ、シアノ、アジド、チオシアネート、トリフルオロメチル、置換もしくは非置換のアルコキシル、置換もしくは非置換のアミノ、置換もしくは非置換のカルボニル、または置換もしくは非置換のC1−6アルキルであり、
R3が、水素または置換もしくは非置換のC1−6アルキルであり、
R4が、置換もしくは非置換のC1−6アルキル、置換もしくは非置換のアリール、または置換もしくは非置換のヘテロアリールであり、
Xが、SまたはOであり、
Yが、O、NH、またはNCH3である、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。 A compound of the formula
R 1 is hydrogen, halogen, hydroxyl, substituted or unsubstituted alkoxyl, substituted or unsubstituted amino, substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted heterocycloalkyl,
R 2 is hydrogen, halogen, hydroxyl, nitro, cyano, azide, thiocyanate, trifluoromethyl, substituted or unsubstituted alkoxyl, substituted or unsubstituted amino, substituted or unsubstituted carbonyl, or substituted or unsubstituted C 1-6 alkyl,
R 3 is hydrogen or substituted or unsubstituted C 1-6 alkyl;
R 4 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl,
X is S or O;
The compound, or a pharmaceutically acceptable salt or prodrug thereof, wherein Y is O, NH, or NCH 3 .
随意に、R1及びR2、R5及びR6、R6及びR7、R7及びR8、またはR8及びR9が、組み合わさって、置換もしくは非置換のアリール、置換もしくは非置換のシクロアルケニル、置換もしくは非置換のヘテロアリール、または置換もしくは非置換のヘテロシクロアルキルを形成する、請求項1に記載の化合物。 The compound is
Optionally, R 1 and R 2 , R 5 and R 6 , R 6 and R 7 , R 7 and R 8 , or R 8 and R 9 are combined to form a substituted or unsubstituted aryl, substituted or unsubstituted 2. The compound of claim 1, forming a cycloalkenyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
Lが、ヘテロアリールであり、
R5、R6、R7、R8、及びR9が、各々独立して、水素及びメトキシから選択される、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。 A compound of the formula
L is heteroaryl;
The compound, or pharmaceutically acceptable salt or prodrug thereof, wherein R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from hydrogen and methoxy.
X1、X2、X3、及びX4が、各々独立して、CH及びNから選択され、
Yが、OまたはNRであり、式中、Rが、水素またはメチルであり、
R2が、水素、C1−6アルキル、ハロゲン、またはトリフルオロアルキルであり、
R5、R6、R7、R8、及びR9が、各々独立して、水素及びメトキシから選択される、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。 A compound of the formula
X 1 , X 2 , X 3 , and X 4 are each independently selected from CH and N;
Y is O or NR, wherein R is hydrogen or methyl;
R 2 is hydrogen, C 1-6 alkyl, halogen, or trifluoroalkyl;
The compound, or pharmaceutically acceptable salt or prodrug thereof, wherein R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from hydrogen and methoxy.
X1が、OまたはNCH3であり、
X2が、CHまたはNであり、
Yが、O、NH、またはNCH3であり、
R5、R6、R7、R8、及びR9が、各々独立して、水素及びメトキシから選択される、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。 A compound of the formula
X 1 is O or NCH 3 ;
X 2 is CH or N;
Y is O, NH, or NCH 3 ;
The compound, or pharmaceutically acceptable salt or prodrug thereof, wherein R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from hydrogen and methoxy.
R1及びR2が、各々独立して、水素、置換もしくは非置換のアミノ、及び置換もしくは非置換のカルボニルから選択される、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。 A compound of the formula
The compound, or pharmaceutically acceptable salt or prodrug thereof, wherein R 1 and R 2 are each independently selected from hydrogen, substituted or unsubstituted amino, and substituted or unsubstituted carbonyl.
Xが、CH2、NH、またはOである、前記化合物、またはその薬学的に許容される塩もしくはプロドラッグ。 A compound of the formula
The compound, or a pharmaceutically acceptable salt or prodrug thereof, wherein X is CH 2 , NH, or O.
Wherein the composition is contacted in vivo, the composition according to any one of claims 12 to 18.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361788353P | 2013-03-15 | 2013-03-15 | |
US61/788,353 | 2013-03-15 | ||
PCT/US2014/027079 WO2014152213A2 (en) | 2013-03-15 | 2014-03-14 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016515131A JP2016515131A (en) | 2016-05-26 |
JP2016515131A5 true JP2016515131A5 (en) | 2017-04-20 |
JP6514680B2 JP6514680B2 (en) | 2019-05-15 |
Family
ID=51581684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016502329A Active JP6514680B2 (en) | 2013-03-15 | 2014-03-14 | Coumarin derivatives and methods of use in the treatment of cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
Country Status (10)
Country | Link |
---|---|
US (1) | US9815825B2 (en) |
EP (1) | EP2970248B1 (en) |
JP (1) | JP6514680B2 (en) |
KR (1) | KR20150131309A (en) |
CN (1) | CN105121437B (en) |
AU (1) | AU2014240026B2 (en) |
CA (1) | CA2903103C (en) |
HK (1) | HK1218420A1 (en) |
MX (1) | MX2015013173A (en) |
WO (1) | WO2014152213A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012158913A2 (en) | 2011-05-17 | 2012-11-22 | Discoverybiomed Inc. | Treating protein folding disorders with small molecule cftr correctors |
US9546176B2 (en) | 2012-11-20 | 2017-01-17 | Discoverybiomed, Inc. | Small molecule bicyclic and tricyclic CFTR correctors |
EP2922852A4 (en) | 2012-11-20 | 2016-05-25 | Discoverybiomed Inc | Small molecule cftr correctors |
CA2903107C (en) | 2013-03-15 | 2021-11-02 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating hyperproliferative diseases |
WO2014152213A2 (en) | 2013-03-15 | 2014-09-25 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
WO2015196071A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
MX2017004543A (en) | 2014-10-06 | 2017-10-04 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator. |
WO2016105477A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
MA41253A (en) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR |
WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
CA2993450C (en) | 2015-07-24 | 2023-10-24 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
CN109563047A (en) | 2016-04-07 | 2019-04-02 | 蛋白质平衡治疗股份有限公司 | Containing silicon atom according to cutting down Kato analog |
MA45397A (en) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR |
CA3041811A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
EP3532467A1 (en) | 2016-10-26 | 2019-09-04 | Proteostasis Therapeutics, Inc. | Pyridazine derivatives, compositions and methods for modulating cftr |
US20190256474A1 (en) | 2016-10-26 | 2019-08-22 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
WO2018201126A1 (en) | 2017-04-28 | 2018-11-01 | Proteostasis Therapeutics, Inc. | 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity |
US20210369749A1 (en) | 2017-10-06 | 2021-12-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
WO2019136314A1 (en) | 2018-01-05 | 2019-07-11 | The Curators Of The University Of Missouri | Compounds and methods for treatment of cystic fibrosis |
EP3846801A1 (en) | 2018-09-09 | 2021-07-14 | Qanatpharma AG | Use of cftr modulators for treating cerebrovascular conditions |
CN110156761B (en) * | 2019-06-18 | 2022-08-09 | 郑州大学 | Compound containing coumarin-biphenyl skeleton, preparation method and application thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5566580A (en) * | 1978-11-11 | 1980-05-20 | Kaken Pharmaceut Co Ltd | Coumarin derivative, its preparation and antiallergic agent containing the same as effective component |
US20030055263A1 (en) * | 2001-07-11 | 2003-03-20 | Boehringer Ingelheim Pharma Kg | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production |
DE10133665A1 (en) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carboxylic acid derivatives, medicaments containing these compounds, their use and preparation |
US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
AU2003245935A1 (en) | 2002-06-13 | 2003-12-31 | Novuspharma S.P.A. | Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells |
MX2007004488A (en) * | 2004-10-13 | 2007-09-11 | Wyeth Corp | N-benzenesulfonyl substituted anilino-pyrimidine analogs. |
WO2006044682A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
CN101076332A (en) * | 2004-10-13 | 2007-11-21 | Ptc医疗公司 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
US20090012148A1 (en) * | 2005-11-01 | 2009-01-08 | Maxfield Frederick R | Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis |
CN101351208A (en) * | 2005-11-01 | 2009-01-21 | 康乃尔研究基金会有限公司 | Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis |
EP2581451B1 (en) * | 2007-12-13 | 2016-03-09 | Indiana University Research and Technology Corporation | Compounds for inhibiting mammalian s-nitrosoglutathione reductase |
EP2411529A4 (en) | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | N-linked glycan biosynthesis modulators |
ITMI20111068A1 (en) * | 2011-06-14 | 2012-12-15 | Azienda Ospedaliera Universitaria I Ntegrata Di Ve | TRIMETHYLANGELICINE AS A CFTR CORRECTOR IN BRONCHIAL EPITHELIUM CELLS |
WO2014152213A2 (en) | 2013-03-15 | 2014-09-25 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
CA2903107C (en) * | 2013-03-15 | 2021-11-02 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating hyperproliferative diseases |
-
2014
- 2014-03-14 WO PCT/US2014/027079 patent/WO2014152213A2/en active Application Filing
- 2014-03-14 US US14/775,010 patent/US9815825B2/en active Active
- 2014-03-14 MX MX2015013173A patent/MX2015013173A/en active IP Right Grant
- 2014-03-14 AU AU2014240026A patent/AU2014240026B2/en active Active
- 2014-03-14 CN CN201480009649.8A patent/CN105121437B/en active Active
- 2014-03-14 EP EP14767955.9A patent/EP2970248B1/en active Active
- 2014-03-14 CA CA2903103A patent/CA2903103C/en active Active
- 2014-03-14 KR KR1020157029643A patent/KR20150131309A/en not_active Application Discontinuation
- 2014-03-14 JP JP2016502329A patent/JP6514680B2/en active Active
-
2016
- 2016-06-07 HK HK16106493.1A patent/HK1218420A1/en unknown